Cardiometabolic
The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome
A 5- and 10-year MRI follow-up found that some reductions in visceral fat persisted even after participants regained their lost body weight. Greater visceral fat loss during the original lifestyle interventions was associated with better long-term metabolic health and a lower risk of type 2 diabetes. The findings challenge a system that often defines success,…
When diabetes tech fails, personalised care fails with it
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.
MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
ENDO 2026 reveals the GLP-1 revolution’s real challenge: delivery
Cholesterol prevention is moving earlier. Is Europe ready to treat inherited risk before adulthood?
Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
WHO is preparing to ration the obesity drug revolution before it becomes another access disaster
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.